Ryvu Therapeutics Presents Updated Clinical and Preclinical Data on RVU120 at the 2022 European Hematology Association (EHA) Congress
– Clinically meaningful benefit of RVU120 monotherapy: a complete remission (CR) in a DNMT3A/NPM1-mutated AML patient; more than…